Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk - Summary - MDSpire

Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk

  • By

  • Hideyuki Fukui

  • Teppei Yoshioka

  • Katsuhiko Sato

  • Yuki Makino

  • Hiromitsu Onishi

  • Atsushi Nakamoto

  • Takashi Ota

  • Toru Honda

  • Feier Ding

  • Yukihiro Enchi

  • Daisaku Yamada

  • Yasunari Fukuda

  • Hidetoshi Eguchi

  • Takahiro Kodama

  • Noriyuki Tomiyama

  • July 10, 2026

Share

Objective:

To test the hypothesis that cyst shrinkage in IPMN is associated with a higher risk of concomitant pancreatic ductal adenocarcinoma (PDAC).

Approach:
  • Study Design: A retrospective cohort study reanalyzing a previously described cohort of patients with pancreatic cystic lesions at The University of Osaka Hospital.
  • Patient Selection: From 2030 patients with pancreatic cystic lesions, 1137 patients with presumed IPMN were enrolled after applying specific exclusion criteria.
  • Imaging and Analysis: Cyst size was measured using CT and/or MRI, and the annual cyst size change rate was calculated to assess growth or shrinkage.
Key Findings:
  • Cyst shrinkage may indicate an increased risk of concomitant PDAC rather than benign regression.
  • Prior studies suggested that cyst shrinkage was generally associated with neutral or protective trends regarding malignancy.
Interpretation:

The findings suggest that shrinking cysts in IPMN patients could be a marker for higher PDAC risk.

Limitations:
  • The study is retrospective, which may introduce biases.
  • Exclusion criteria may limit the generalizability of the findings.
Conclusion:

Cyst shrinkage in IPMN may not be a reassuring finding.

Sources:

Original Source(s)

Shrinkage paradox in intraductal papillary mucinous neoplasms is associated with higher concomitant pancreatic cancer risk

  • by Hideyuki Fukui, Teppei Yoshioka, Katsuhiko Sato, Yuki Makino, Hiromitsu Onishi, Atsushi Nakamoto, Takashi Ota, Toru Honda, Feier Ding, Yukihiro Enchi, Daisaku Yamada, Yasunari Fukuda, Hidetoshi Eguchi, Takahiro Kodama, Noriyuki Tomiyama

  • July 10, 2026

Related Content

Trends in liver failure-related mortality among middle-aged and older adults with digestive system malignant tumors in the United States, 1999–2023

From Peak Performance to Precision Healthcare

Travis Nemkov and Angelo D’Alessandro discuss how molecular profiling in elite athletes could inform personalized exercise, healthy aging, and cancer recovery

Immune checkpoint inhibitor-driven smooth muscle cell phenotypic modulation: a potential contributor to atherosclerotic risk associated with these therapies